



The Immune System and Aging Related Cancer Risk

Yi Cheng Fu*

Department of Geriatrics, Peking University Third Hospital, Beijing, China

ABOUT THE STUDY

Cancer is one of the leading causes of death worldwide, and it is a disease that affects individuals of all ages. However, aging is a significant risk factor for the development of cancer, with the incidence of cancer increasing with age. Although the relationship between aging and cancer is complex and multifaceted, researchers are continuing to probe the role of aging in cancer to better understand this relationship and develop effective prevention and treatment strategies.

Aging is a natural process that occurs as an individual's body undergoes physiological changes over time. These changes include the accumulation of DNA damage, the impairment of DNA repair mechanisms, and a decline in the body's immune function. These changes can all contribute to the development of cancer by creating an environment that is conducive to the growth and proliferation of cancer cells. One of the key mechanisms that link aging and cancer is the process of cellular senescence [1,2]. Cellular senescence is a cellular response that occurs when cells experience significant stress or damage, such as DNA damage, telomere dysfunction, or oxidative stress. This response involves the permanent cessation of cell division and the secretion of factors that can either promote or inhibit tumour growth [3].

In healthy individuals, cellular senescence is thought to act as a tumour suppressor mechanism, preventing the proliferation of damaged cells that could potentially develop into cancer. However, as an individual ages, the accumulation of senescent cells can contribute to the development of cancer by creating a pro-inflammatory microenvironment that promotes the growth and survival of cancer cells [4,5].

In addition to cellular senescence, other age-related changes in the body can contribute to the development of cancer. For example, changes in the composition of the gut microbiome, which occur with aging, can alter the immune system's response to tumours, leading to increased tumour growth and metastasis. The immune system also plays a critical role in the development and progression of cancer [6]. As individuals age, the immune system undergoes significant changes, including a decline in the

function of T cells and natural killer cells, which can impair the immune system's ability to detect and eliminate cancer cells.

Furthermore, the aging process can also lead to changes in the structure and function of the tumour microenvironment. For example, aging-associated changes in the extracellular matrix can create an environment that promotes the growth and invasion of cancer cells [7,8]. Overall, the relationship between aging and cancer is complex and multifaceted, with a wide range of factors contributing to the development and progression of cancer in older individuals. However, researchers are continuing to probe the role of aging in cancer to better understand this relationship and develop effective prevention and treatment strategies [9].

One promising approach in addressing the link between aging and cancer is the development of targeted therapies that specifically target age-related changes in the tumour microenvironment. For example, drugs that target senescent cells, such as Senolytics, have shown promise in preclinical studies by reducing the number of senescent cells in the tumour microenvironment and improving immune function [10]. In addition to targeted therapies, lifestyle interventions, such as exercise and diet, can also play an important role in reducing the risk of cancer in older individuals. For example, exercise has been shown to improve immune function and reduce the accumulation of senescent cells in the body, while dietary interventions, such as calorie restriction, have been shown to delay the onset of age-related diseases, including cancer [11].

Aging is a significant risk factor for the development of cancer, with a wide range of age-related changes contributing to the development and progression of cancer in older individuals [12]. However, by understanding the complex interplay between aging and cancer, researchers can develop targeted therapies and lifestyle interventions that can reduce the risk of cancer and improve outcomes for older individuals with cancer.

REFERENCES

1. Foerster F, Gairing SJ, Ilyas SI, Galle PR. Emerging immunotherapy for HCC: A guide for hepatologists. *Hepatology*. 2022; 75(6): 1604-1626.

Correspondence to: Yi Cheng Fu, Department of Geriatrics, Peking University Third Hospital, Beijing, China, E-mail: Chenfu999@yahoo.com

Received: 21-Feb-2023, Manuscript No. HAR-23-22830; **Editor assigned:** 24-Feb-2023, PreQC No. HAR-23-22830 (PQ); **Reviewed:** 13-Mar-2023, QC No. HAR-23-22830; **Revised:** 20-Mar-2023, Manuscript No. HAR-23-22830 (R); **Published:** 27-Mar-2023, DOI: 10.35248/2261-7434.23.12.160

Citation: Fu YC (2023) The Immune System and Aging Related Cancer Risk. *Healthy Aging Res*. 12:160

Copyright: © 2023 Fu YC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

2. Braghini MR, Lo Re O, Romito I, Fernandez-Barrena MG, Barbaro B, Pomella S, et al. Epigenetic remodelling in human hepatocellular carcinoma. *J Exp Clin Cancer Res.* 2022; 41(1):1-21.
3. Fischer F, Grigolon G, Benner C, Ristow M. Evolutionarily conserved transcription factors as regulators of longevity and targets for geroprotection. *Physiol Rev.* 2022; 102(3):1449-1494.
4. McHugh D, Gil J. Senescence and aging: Causes, consequences, and therapeutic avenues. *J Cell Biol.* 2018; 217(1):65-77.
5. Blagosklonny MV. Cell senescence, rapamycin and hyperfunction theory of aging. *Cell Cycle.* 2022; 21(14):1456-1467.
6. Zhao Y, Oreskovic E, Zhang Q, Lu Q, Gilman A, Lin YS, et al. Transposon-triggered innate immune response confers cancer resistance to the blind mole rat. *Nat Immunol.* 2021; 22(10):1219-1230.
7. Engelmann C, Tacke F. The potential role of cellular senescence in non-alcoholic fatty liver disease. *Int J Mol Sci.* 2022; 23(2):652.
8. Avelar RA, Ortega JG, Tacutu R, Tyler EJ, Bennett D, Binetti P, et al. A multidimensional systems biology analysis of cellular senescence in aging and disease. *Genome Biol.* 2020; 21(1):1-22.
9. Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. *Bioinformatics.* 2010; 26(12):1572-1573.
10. Wang Z, Cao L, Zhou S, Lyu J, Gao Y, Yang R. Construction and validation of a novel pyroptosis-related four-lncRNA prognostic signature related to gastric cancer and immune infiltration. *Front Immunol.* 2022; 13.
11. Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. *Nat Med.* 2018; 24(10):1550-1558.
12. Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, et al. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. *Cancer cell.* 2007; 11(6):555-569.